BSE: 0 | NSE: JFLLIFE | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that JFL Life Sciences Ltd is a average quality company.
The key valuation ratios of JFL Life Sciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of JFL Life Sciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 8.7% | 11.8% | 10.3% | 23.1% | 15.5% | 11.5% | - |
| Value Creation Index ⓘ | -0.4 | -0.2 | -0.3 | 0.7 | 0.1 | -0.2 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||
| Sales ⓘ | 31.8 | 30.2 | 32.8 | 33.6 | 42.8 | 46.6 | 47 |
| Sales YoY Gr. | - | -5.1% | 8.6% | 2.5% | 27.5% | 8.7% | - |
| Adj EPS ⓘ | 0.2 | 0.2 | 0.3 | 1.2 | 0.9 | 1 | 1 |
| YoY Gr. | - | 22.2% | 27.3% | 314.3% | -26.7% | 17.7% | - |
| BVPS (₹) ⓘ | 3 | 3.3 | 3.6 | 4.7 | 9.8 | 10.8 | 17.5 |
| Adj Net Profit ⓘ | 0.3 | 0.4 | 0.5 | 2.8 | 2.8 | 3.3 | 3 |
| Cash Flow from Ops. ⓘ | -3 | 3.2 | -5.9 | 2.3 | -9.1 | 8.4 | - |
| Debt/CF from Ops. ⓘ | -2.8 | 2.9 | -2.9 | 6.8 | -0.8 | 0.7 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | 7.9% | 12.4% | 8.7% | ||||
| Adj EPS ⓘ | NA | 40.9% | 52.9% | 17.7% | ||||
| BVPSⓘ | NA | 28.8% | 44.8% | 10.2% | ||||
| Share Price | - | - | - | -25.7% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 6 | 6.9 | 8.8 | 30.6 | 12.9 | 9.8 | 7.1 |
| Op. Profit Mgn % ⓘ | 4.2 | 6.2 | 6.6 | 16 | 9.2 | 9.8 | NAN |
| Net Profit Mgn % ⓘ | 1 | 1.2 | 1.6 | 8.3 | 6.6 | 7.1 | 7.1 |
| Debt to Equity ⓘ | 1.7 | 1.7 | 2.5 | 1.4 | 0.2 | 0.2 | - |
| Working Cap Days ⓘ | 0 | 197 | 231 | 345 | 354 | 338 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 103 | 108 | 172 | 182 | 222 | 0 |
Sales growth is growing at healthy rate in last 3 years 12.41%
Net Profit is growing at healthy rate in last 3 years 52.86%
Debt to equity has declined versus last 3 years average to 0.16
Return on Equity has declined versus last 3 years average to 7.10%
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 1 | - |
| TTM Sales (₹ Cr.) | 46.6 | - |
| BVPS (₹.) ⓘ | 17.5 | - |
| Reserves (₹ Cr.) ⓘ | 25 | - |
| P/BV ⓘ | 1.85 | - |
| PE ⓘ | 32.27 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 0.00 / 0.00 |
| All Time Low / High (₹) | - / - |
| Market Cap (₹ Cr.) | 107 |
| Equity (₹ Cr.) | 33 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 44.3 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|
| Sales | 32 | 30 | 33 | 34 | 43 | 47 |
| Operating Expenses ⓘ | 30 | 28 | 31 | 28 | 39 | 42 |
| Manufacturing Costs | 0 | 0 | 0 | 0 | 0 | 0 |
| Material Costs | 29 | 26 | 29 | 26 | 36 | 39 |
| Employee Cost | 1 | 1 | 1 | 1 | 2 | 2 |
| Other Costs ⓘ | 0 | 0 | 1 | 1 | 1 | 1 |
| Operating Profit ⓘ | 1 | 2 | 2 | 5 | 4 | 5 |
| Operating Profit Margin (%) | 4.2% | 6.2% | 6.6% | 16.0% | 9.2% | 9.8% |
| Other Income ⓘ | 0 | 0 | 0 | 1 | 2 | 1 |
| Interest ⓘ | 1 | 1 | 1 | 2 | 1 | 1 |
| Depreciation ⓘ | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 0 | 0 | 1 | 4 | 4 | 4 |
| Tax ⓘ | 0 | 0 | 0 | 1 | 1 | 0 |
| Profit After Tax | 0 | 0 | 1 | 3 | 3 | 3 |
| PAT Margin (%) | 1.0% | 1.2% | 1.7% | 8.4% | 6.6% | 7.1% |
| Adjusted EPS (₹) | 0.2 | 0.2 | 0.3 | 1.2 | 0.9 | 1.0 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 8% |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 5 | 5 | 7 | 11 | 32 | 36 | ||||
| Share Capital ⓘ | 0 | 0 | 0 | 8 | 11 | 11 | ||||
| Reserves ⓘ | 5 | 5 | 6 | 3 | 21 | 25 | ||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Debt | 7 | 8 | 14 | 14 | 7 | 6 | ||||
| Long Term Debt | 3 | 1 | 8 | 8 | 1 | 1 | ||||
| Short Term Debt | 4 | 6 | 5 | 5 | 6 | 5 | ||||
| Trade Payables | 1 | 9 | 5 | 15 | 7 | 10 | ||||
| Others Liabilities ⓘ | 3 | 2 | 4 | 8 | 2 | 5 | ||||
| Total Liabilities ⓘ | 16 | 24 | 29 | 48 | 49 | 57 | ||||
Fixed Assets | ||||||||||
| Gross Block | 3 | 6 | 8 | 9 | 9 | 15 | ||||
| Accumulated Depreciation | 1 | 1 | 1 | 2 | 2 | 3 | ||||
| Net Fixed Assetsⓘ | 2 | 5 | 7 | 7 | 7 | 12 | ||||
| CWIP ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Investmentsⓘ | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Inventories | 2 | 4 | 6 | 15 | 13 | 16 | ||||
| Trade Receivables | 10 | 13 | 12 | 20 | 22 | 25 | ||||
| Cash Equivalents | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Others Assetsⓘ | 2 | 3 | 5 | 6 | 7 | 3 | ||||
| Total Assets ⓘ | 16 | 24 | 29 | 48 | 49 | 57 | ||||
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -3 | 3 | -6 | 2 | -9 | 8 |
| PBT ⓘ | 0 | 0 | 1 | 4 | 4 | 4 |
| Adjustment ⓘ | 1 | 1 | 1 | 2 | 2 | 1 |
| Changes in Working Capital ⓘ | -4 | 1 | -8 | -4 | -14 | 3 |
| Tax Paid ⓘ | 0 | 0 | 0 | 0 | -1 | 0 |
| Cash Flow From Investing Activity ⓘ | -1 | -3 | -2 | -1 | 1 | -6 |
| Capex | -1 | -3 | -2 | -2 | 0 | -6 |
| Net Investments | 0 | 0 | 0 | 1 | 1 | 0 |
| Others ⓘ | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow From Financing Activityⓘ | 4 | 0 | 7 | -1 | 8 | -2 |
| Net Proceeds from Shares ⓘ | 1 | 0 | 1 | 2 | 18 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | -7 | 0 |
| Interest Paid ⓘ | -1 | -1 | -1 | -2 | -1 | -1 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 4 | 1 | 7 | -1 | -2 | -1 |
| Net Cash Flow ⓘ | 0 | 0 | 0 | 0 | 0 | 0 |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 6.03 | 6.94 | 8.85 | 30.94 | 12.9 | 9.75 | ||||
| ROCE (%) | 8.71 | 11.8 | 10.32 | 23.14 | 15.45 | 11.46 | ||||
| Asset Turnover Ratio | 1.97 | 1.49 | 1.23 | 0.87 | 0.88 | 0.88 | ||||
| PAT to CFO Conversion(x) | N/A | N/A | -6 | 0.67 | -3 | 2.67 | Working Capital Days | |||
| Receivable Days | 111 | 135 | 136 | 172 | 180 | 187 | ||||
| Inventory Days | 20 | 33 | 53 | 112 | 118 | 112 | ||||
| Payable Days | 18 | 71 | 85 | 142 | 117 | 81 | ||||
The Company was incorporated as ‘JFL Life Sciences Private Limited’ on April 25, 2010 as a private limited company under the Companies Act, 1956 with the Registrar of Companies, Gujarat, Dadra and Nagar Havelli. Pursuant to a special resolution of company’s Shareholders passed in the extra-ordinary general meeting held on February 10, 2022, the Company was converted from a private limited company to public limited company and consequently, the name of the Company was changed to ‘JFL Life Sciences Limited’, and a fresh certificate of incorporation dated March 3, 2022 was issued to the Company by the Registrar of Companies, Gujarat at Ahmedabad.
Headquartered in Ahmedabad, Gujarat, JFL Life Sciences is engaged in the business of manufacturing of pharmaceutical products. The company is engaged in domestic as well as international business. With market presence in PAN India, products of JFL is supplied to 10 developed and developing countries throughout the World. To maintain its competitiveness and to further the cause of health care JFL has laid a strong R&D foundation and a FDA approved state of the art manufacturing facility near Ahmedabad. It is a manufacturing company, so its sales strategy is to sell its products in bulk to pharmaceuticals marketers and traders who in turn provide the channel for sales to customers. It does not sell it under any brand name and it use the same strategy for both domestic & international market. The company exports its products majorly to African countries, Middle Eastern countries and CIS countries, mainly through merchant exporters. The company is registered with the MOH of Kenya, Nigeria, Yemen, Cambodia & Myanmar for manufacturing of a particular product. Few of its products are also registered with Ukraine, Uzbekistan, Kazakhstan (CIS countries) through merchants.
Business area of the company
JFL Life Sciences manufactures a wide range of pharmaceutical formulations. The company’s major products types are Dry powder injections; Tablets & Capsules (B-Lactam) solid oral dosage form; Tablet and capsules (General); and Oral Rehydration Solutions (ORS).
Major Events and Milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
